Clinical Pharmacist Impact Study

NCT ID: NCT07269002

Last Updated: 2025-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-15

Study Completion Date

2025-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluated a pharmacist-led medication-safety program in hospitalized patients. The program included routine inpatient medication review and the use of smartphone-based clinical decision-support applications to identify potential medication issues and support therapeutic decision-making. The study was conducted in both adult and pediatric inpatients as part of routine clinical care. No investigational drugs or devices were used.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was conducted to assess the impact of a structured pharmacist-led medication-safety program implemented across inpatient units in a multispecialty hospital. The program incorporated routine clinical pharmacist review of inpatient medication therapy and the use of smartphone-based clinical decision-support applications to assist with identifying potential medication issues and supporting therapeutic optimization.

The intervention was applied prospectively in both adult and pediatric inpatients receiving pharmacologic treatment. All activities were performed as part of routine clinical service enhancement, without the use of investigational drugs or devices. The study focused on evaluating medication-safety indicators, clinical process measures, and patient-related outcomes before and after implementation of the pharmacist-led program.

The aim of the project was to enhance medication accuracy, reduce preventable medication-related problems, and support evidence-based decision-making in a real-world hospital environment. This description summarizes the overall service-improvement approach without disclosing study-specific operational details.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medication Safety Preventable Medication Harm Pharmacotherapy Optimization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Usual inpatient medication practices before implementation of the pharmacist-led safety program.

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention

Structured pharmacist-led medication review and safety support using smartphone clinical decision-support applications.

Group Type OTHER

Pharmacist-Led Medication Safety Program

Intervention Type OTHER

A structured clinical pharmacist program that includes inpatient medication review, identification of potential medication-related problems, and use of smartphone-based clinical decision-support applications to support therapeutic decision-making and enhance medication safety practices.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacist-Led Medication Safety Program

A structured clinical pharmacist program that includes inpatient medication review, identification of potential medication-related problems, and use of smartphone-based clinical decision-support applications to support therapeutic decision-making and enhance medication safety practices.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalized patients receiving medication therapy

Adult and pediatric inpatients

Patients receiving at least one scheduled medication dose during admission

Exclusion Criteria

* Patients not receiving any pharmacologic treatment

Patients admitted for procedures with no medication administration

Patients discharged before assessment could be performed
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beni-Suef University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Mohammed Abd Elhamid Mohammed Tony

Clinical Pharmacist and Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Coordination Unit

Banī Suwayf, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

F PH-BSU-HREC-0001025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.